Abstract #1993

Detection of the Multiple Sclerosis Drug Siponimod Using Fluorine-19 Magnetic Resonance Imaging

Ludger Starke^1,2, Mariya Aravina¹, Jason M. Millward¹, Thoralf Niendorf^1,3, and Sonia Waiczies¹

¹Berlin Ultrahigh Field Facility, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany, ²Digital Health Center, Hasso Plattner Institute, Potsdam, Germany, ³Experimental and Clinical Research Center (ECRC), A Joint Cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany

Synopsis

Siponimod is a fluorinated drug approved for treatment of secondary progressive multiple sclerosis. We detect ¹⁹F-MR signal in the liver, brain, kidneys, and thymus, and achieve the first ¹⁹F-MR images of a disease modifying drug, both in the liver and brain ex vivo and in a proof-of-concept in vivo experiment. Clear concentration differences between lobes of the liver or regions of the CNS can be observed. We have demonstrated the feasibility of using ¹⁹F-MRI to study the distribution of disease modifying drugs and improve our understanding of pharmacokinetics or guide therapeutic decisions.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.